obesity

BioAge Labs presents preclinical data demonstrating apelin receptor (APJ) agonist potential for diabetic obesity and heart failure with preserved ejection fraction (HFpEF). APJ activation, acting as an exercise mimetic, enhances the effects of incretin therapy, improving glycemic control and offering cardioprotective benefits. The company is developing next-generation APJ agonists, including oral and injectable formulations, with an IND filing planned for 2026, aiming to develop new therapies for obesity and its complications.

Innovent Biologics initiated a Phase 3 trial (GLORY-OSA) in China for mazdutide, a dual GCG and GLP-1 receptor agonist. The study will evaluate the drug’s efficacy and safety in Chinese patients with obesity and moderate-to-severe obstructive sleep apnea (OSA). Mazdutide has shown potential in weight loss and metabolic improvements, representing a potential treatment for a condition that affects millions in China, where current diagnosis rates are low. This marks the seventh Phase 3 study for the drug.

Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.